155 related articles for article (PubMed ID: 35816946)
1. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.
Huang Y; Liao J; Liang F; Lin P; Wu S; Ye Y; Gao M; Chen R; Zeng H; Yin X; Jiang Y; Ouyang N; Han P; Huang X
Int Immunopharmacol; 2022 Sep; 110():108846. PubMed ID: 35816946
[TBL] [Abstract][Full Text] [Related]
2. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.
Valero C; Golkaram M; Vos JL; Xu B; Fitzgerald C; Lee M; Kaplan S; Han CY; Pei X; Sarkar R; Boe LA; Pandey A; Koh ES; Zuur CL; Solit DB; Pawlowski T; Liu L; Ho AL; Chowell D; Riaz N; Chan TA; Morris LG
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561583
[TBL] [Abstract][Full Text] [Related]
3. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
4. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
Pan D; Hu AY; Antonia SJ; Li CY
J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
[TBL] [Abstract][Full Text] [Related]
5. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
6. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
7. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis.
Rodrigo JP; Sánchez-Canteli M; Otero-Rosales M; Martínez-Camblor P; Hermida-Prado F; García-Pedrero JM
J Transl Med; 2024 Feb; 22(1):135. PubMed ID: 38311741
[TBL] [Abstract][Full Text] [Related]
8. miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma.
Xia Y; Wang Q; Huang X; Yin X; Song J; Ke Z; Duan X
Biomed Res Int; 2020; 2020():1686480. PubMed ID: 33490233
[TBL] [Abstract][Full Text] [Related]
9. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma.
Zhou C; Wang S; Shen Z; Shen Y; Li Q; Shen Y; Huang J; Deng H; Ye D; Zhan G; Li J
J Clin Lab Anal; 2022 Jan; 36(1):e24113. PubMed ID: 34783061
[TBL] [Abstract][Full Text] [Related]
10. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
12. Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma.
Huang Y; Liu H; Liu B; Chen X; Li D; Xue J; Li N; Zhu L; Yang L; Xiao J; Liu C
BMC Med Genomics; 2024 Feb; 17(1):49. PubMed ID: 38331768
[TBL] [Abstract][Full Text] [Related]
13. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
Gupta R; Strbenac D; Satgunaseelan L; Cheung VK; Narayanappa H; Ashford B; Mitchell J; Thind A; Palme CE; Ch'ng S; Low TH; Wykes J; Willet CE; Chew T; Yang J; Ranson M; Clark JR
Mod Pathol; 2023 Aug; 36(8):100190. PubMed ID: 37080394
[TBL] [Abstract][Full Text] [Related]
14. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
15.
Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
[TBL] [Abstract][Full Text] [Related]
16. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
17. Mast cell marker gene signature in head and neck squamous cell carcinoma.
Cai Z; Tang B; Chen L; Lei W
BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596
[TBL] [Abstract][Full Text] [Related]
18. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an ADME-Related Gene Signature for Survival, Treatment Outcome and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma.
Tang X; Li R; Wu D; Wang Y; Zhao F; Lv R; Wen X
Front Immunol; 2022; 13():905635. PubMed ID: 35874705
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
